Cingulate Inc.

NASDAQ:CING

Biotechnology

Healthcare
$5.11 -0.95%

-$0.05 today

Market cap
$76.46M
Beta
-0.91
P/E (TTM)
-1.0
EPS (TTM)
-$5.10
52W Low $3.16High $11.89

Volume 0.95M

Average 0.46M

CING Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Cingulate Inc.NASDAQ: CING

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 5.43M shares rose 48.9% year over year, behind the +53.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +56.6% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +48.9% toward the trailing-twelve-month pace of +53.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
5.43M+0.0% QoQ
Last fiscal yearDec 2025
5.43M+42.5% YoY
LTMMar 2026
5.17M+53.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+48.9%——
1 year+42.5%——
3-year CAGR+56.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
5.43M USD
Year-over-year change
+42.5%
4-year CAGR
+40.0%

Weighted Avg Shares (Diluted) vs competitors

How CING compares with its peers on the latest reported figures

  • CING's LTM Mar 2026 weighted avg shares (diluted) of 5.17M shares is the lowest of the 2 companies compared; the peer median is 17.05M shares.
  • Its year-over-year change of +53.1% is the lowest of 2, against a peer median of +639.7%.
  • Over three fiscal years its annual growth of +56.6% compares with a peer median of +212.8%.
CING Competitors Peer median
Weighted Avg Shares (Diluted) for CING and competitors
Company Period LTM YoY 3-year CAGR
LIXTLixte Biotechnology Holdings, Inc.LTM Mar 202617.05M +639.7%+212.8%
CINGCingulate Inc.LTM Mar 20265.17M +53.1%+56.6%
Peer median (excluding CING) 17.05M+639.7%+212.8%

Competitors are the stored peer set for CING. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development8.41M9M15.49M9.45M9.77M
Selling, General & Admin12.27M8.51M7.27M6.2M10.16M
Operating Expenses20.68M17.5M22.76M15.64M19.94M
Depreciation & Amortization708.32K394.01K582.92K653.09K540.89K
EBITDA(19.97M)(17.11M)(22.18M)(14.99M)(19.4M)
EBITDA Margin—————
Operating Income(20.68M)(17.5M)(22.76M)(15.64M)(19.94M)
Operating Margin—————
Interest Income0175775.76K0369.27K
Interest Expense33.41K174K00924.45K
Other Income / Expenses(30.59K)(174.51K)(775.76K)(914.63K)(2.51M)
Income Before Tax(20.71M)(17.68M)(23.53M)(16.56M)(22.45M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(20.71M)(17.68M)(23.53M)(16.56M)(22.45M)
Net Margin—————
EPS (Basic)(55.80)(31.20)(311.99)(10.20)(4.13)
EPS (Diluted)(55.80)(31.20)(311.99)(10.20)(4.13)
Weighted Avg Shares1.41M1.41M2.26M3.81M5.43M
Weighted Avg Shares (Diluted)1.41M1.41M2.26M3.81M5.43M

Cingulate Inc.

NASDAQ:CING

Intrinsic Alpha fair value

Locked

Current Price

$5.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.